Cytokinetics to Host Research and Development Day on Wednesday, December 12, 2012
Senior Management Will Provide Updates Relating to the Company's R&D Activities and Key Opinion Leaders Will Discuss the Potential Applications of Treatments
Panel to Follow: Integrated Support & Care of the ALS Patient
South San Francisco, CA, November 28, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to host its Research and Development Day on Wednesday, December 12, 2012. The event is scheduled to take place from 8:00 AM - 12:00 PM Eastern Time at the New York Grand Hyatt Hotel in New York, New York and will be simultaneously webcast.
Those interested in attending in person should RSVP to email@example.com by December 3rd. In addition, parties may access the live video webcast of this presentation and accompanying slides by visiting the Investor Relations section of the Cytokinetics' website at www.cytokinetics.com. The live audio of the forum will also be accessible by dialing either (866) 999-2985 (United States and Canada) or (706) 679-3078 (International) and typing in the passcode 72489467. The webcast replay of the presentation will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website following the event. The replay will also be available via telephone from December 12, 2012 at 1:00 PM Eastern Time until December 26, 2012 by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (International) and typing in the passcode 72489467.
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing tirasemtiv, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Jodi L. Goldstein
Manager, Marketing & Corporate Communications